Yazan_Madanat

Yazan Madanat MD

UT Southwestern Simmons Comprehensive Cancer Center

Appearances

$Thumbnail for Results From the Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion-Dependent Non-del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents$
Results From the Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion-Dependent Non-del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents
Date
April 6, 2024
Abstract: JNCCN23-0640 https://jnccn.org/view/journal... [https://jnccn.org/view/journals/jnccn/22/2.5/article-pCLO24-079…
Speaker
Yazan Madanat, MD
UT Southwestern Simmons Comprehensive Cancer Center
Updates in Oncology: Oral Presentations from the NCCN Poster Sessions
Date
April 6, 2024
Not a CE-certified activity…
Moderator
Wallace Akerley, MD
Huntsman Cancer Institute
Speakers
Alexandrina Balanean, MPH
Lead Publication Scientist, Strategic Research, Cardinal Health Inc
Danielle Brabender, MD
University of Southern California Keck School of Medicine
Xiaohan Hu, PhD, MPH
Merck & Co Inc
Yazan Madanat, MD
UT Southwestern Simmons Comprehensive Cancer Center
Adrianna Oraiqat, BS
Pancreas Cancer Care Coordinator, Moffitt Cancer Center